
































































© Translational Lung Cancer Research. All rights reserved.   Transl Lung Cancer Res 2021;10(4):2088-2100 | http://dx.doi.org/10.21037/tlcr-20-458
Introduction
Thymic epithelial tumours (TETs) originate from the 
thymus and are classified as thymoma, thymic carcinoma 
(TC) or thymic neuroendocrine tumour (TNET) (1).
The incidence of all TETs is about 1.3–3.2 cases per 
million worldwide and most commonly diagnosed between 
the age of 40–60 years (2). 
Thymomas are the most common anterior mediastinal 
tumour, accounting for up to 50% of all anterior mediastinal 
masses (3). The most relevant differential diagnoses are 
lymphomas and germ-cell tumours.
Thymic carcinomas are even less frequent (4), TNETs 
are the rarest of the three accounting for approximately 
0.4% of all carcinoid tumours (5).
One-third of patients with thymoma present with 
autoimmune disorders, mainly myasthenia gravis which 
is particularly common in type AB, B1 and B2 thymomas 
and almost always associated with anti-acetylcholine 
receptor antibodies (6). Myasthenia gravis is a consequence 
of cross-reactivity of anti-thymoma immune response 
with the neuromuscular junction. In patients suffering 
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from paraneoplastic myasthenia gravis, commonly used 
drugs such as ciprofloxacin, beta blockers, calcium 
channel blockers, muscle relaxants and verapamil among 
others, should not be administered as they can worsen 
the symptoms of myasthenia gravis. Contrast-enhanced 
computed tomography (CT) is essential for the diagnosis 
and to define the best strategy of care (7). CT is equal or 
superior to magnetic resonance imaging (MRI) for the 
diagnosis, except in the setting of cystic lesions (8).
Histopathology of TETs is complex and different 
histological classifications have been described in the 
literature. The WHO histologic classification system gives 
a detailed overview of the different histologic subtypes. 
Based on the morphological appearance of TETs and the 
lymphocyte/thymic epithelial cell (TEC) ratio, thymoma 
are classified as types A, AB, B1, B2 and B3 (9,10). 
Depending on the histological subtype, the prognosis of 
TET can vary significantly (11). Thymoma types A, AB, and 
B1 have a good 10-year overall survival (OS) of 90–95%. 
While thymomas show less aggressive behaviour, TC and 
TNET are associated with worse outcomes (12) with 5-year 
overall survival rates of approximately 55% for TC and 
28% to 75% for TNET (13-16).
As a consequence of their rarity, our knowledge about 
the management of patients with TETs is mainly based on 
retrospective series, uncontrolled non-randomised trials or 
expert opinions (17,18). Studies including large numbers of 
patients are rare, especially when investigating multimodal 
treatment options. With the creation of the International 
Thymic Malignancies Interest Group (ITMIG) and 
other thymic working groups (e.g., ESTS, RHYTMIC), 
substantial efforts have been made to optimise the care 
of thymic malignancies (18). The selection of optimal 
management of TETs remains challenging and the role 
of radiotherapy is controversial. The current review will 
highlight TET management with a focus on radiotherapy.
Staging
The Masaoka-Koga classification, which was developed 
in 1981 (19) and revised in 1994 (20), is the most widely 
adopted staging system due to its prognostic significance 
(16,21,22). It is a pathology based grading system only 
assessable after surgical resection of the tumour.
The ITMIG and the Thymic Domain of the Staging 
and Prognostic Factors Committee of the International 
Association for the Study of Lung Cancer (IASLC) has 
developed a TNM classification that has been incorporated 
into the 8th version of the AJCC and UICC staging systems (11) 
(Figure 1). 
In the TNM staging system, Masaoka I, II and some 
stage III TETs correspond to stage I (T1N0M0) tumours. 
Major problem regarding PORT is to identify Masaoka-
Koga stage II and III tumours within the TNM stage 
I group. The recommendation of the current ESMO 
guidelines is to keep decision-making based on the 
Masaoka-Koga system for PORT—until more data is 
available.
Surgery
The optimal therapy for TETs should be determined at a 
multidisciplinary setting (23-26). Treatment strategy for 
TET is primarily based on whether the tumour is resected 
upfront. The evaluation of resectability is based on tumour 
size and the surgeon’s expertise. TNM staging may even 
assist in estimating resectability: stage T1-3 refers to an 
extension amenable to surgical resection, while stage T4 is 
mostly considered unresectable (25).
Complete tumour resection represents the most effective 
therapy and most significant favourable prognostic factor, 
both on DFS and OS (22,27-32). 
Generally, complete thymectomy, including the tumour, 
residual thymus and perithymic fat is preferred for stage 
I-II disease. Recently, the concept of thymectomy in stage I 
leaving residual thymic tissue and peri-thymic fat behind has 
emerged as an option in non-myasthenic TET patients (33). 
In stage III TET infiltrating surrounding structures, en 
bloc removal of all affected structures should be performed. 
Surgical clips should be placed at the time of resection to 
areas of close margins, residual disease or tumour adhesion 
to unresected normal structures to help define target 
volumes for potential PORT.
The ITMIG/IASLC working groups proposed lymph 
node staging, which was the basis for the 8th version of 
the TNM classification. Routine removal of anterior 
mediastinal nodes is recommended, and systematic sampling 
of intrathoracic sites is encouraged in stage III/IV tumours. 
An even more extensive systematic nodal dissection is 
recommended for TC (high rate of lymphatic spread of 
20%) (22,25,34).
For potentially resectable TETs (Masaoka-Koga stage 
III/IVa), a biopsy should be performed and induction 
chemotherapy with or without RT can be considered to 
improve the R0 resection rate as a curative-intent strategy 
(25,26,35-41). Two to four cycles of cisplatin-based 
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Descriptors Masaoka-Koga staging 8th edition of the AJCC staging system
Encapsulation I: macroscopically and microscopically 
completely encapsulated




IIA: microscopic transcapsular invasion T1a: encapsulated; unencapsulated, with or without extension 
into mediastinal fat
IIB: macroscopic invasion into surrounding 
fatty tissue; grossly adherent to but not 
through mediastinal pleura or pericardium
T1b: involvement of mediastinal pleura
Involvement of pleura, 
pericardium, great vessels 
or neighboring organs
III: macroscopic invasion into neighboring 
organs (i.e., pericardium, great vessels, or 
lung)
T2: involvement of pericardium
T3: involvement of lung, brachiocephalic vein, superior vena cava, 
chest wall, phrenic nerve, chest wall, hilar pulmonary vessels
T4: involvement of aorta, arch vessels, main pulmonary artery, 
myocardium, trachea, or esophagus
Nodal involvement IVB: lymphogenous metastasis; hematogenous 
metastasis
N0: no nodal involvement
N1: anterior nodes
N2: deep intrathoracic nodes; cervical nodes
Metastatic spread IVA: pleural dissemination; pericardial 
dissemination
M0: no metastatic disease
IVB: lymphogenous metastasis; hematogenous 
metastasis
M1a: separate pleural nodule(s); pericardial nodule(s)
M1b: pulmonary intraparenchymal nodule; distant organ 
metastasis
IASLC/ITMIG stage T N M Corresponding Masaoka-Koga stage
I T1 N0 M0 I, IIA, IIB, III
II T2 N0 M0 III
IIIA T3 N0 M0 III
IIIB T4 N0 M0 III
IVA T any N1 M0 IVB
T any N0, N1 M1a IVA
IVB T any M0, M1a M0, M1a IVB
T any M1b M1b IVB
Figure 1 Comparison between the Masaoka-Koga staging system and the TNM based (IASLC/ITMIG) staging system for TETs included 
in the AJCC 8th edition cancer staging system manual, adapted from Willmann et al. (17).
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combination regimens should be administered followed by 
radiological restaging to reassess resectability. About 10% of 
these patients will not be eligible for surgery after induction 
chemotherapy. For patients with unresectable disease, RT 
with (or without) chemotherapy is recommended (26). 
Surgery for Masaoka-Koga stage IVa (especially in the case of 
pleural involvement) is not well defined and should be discussed 
in a multidisciplinary team (MDT). Tumour debulking, 
extrapleural pneumonectomy (EPP) and intracavitary pleural 
treatment are additional options for this stage (40,42). 
Radiotherapy 
Radiotherapy is used in various settings for the treatment of 
TETs: after surgical resection as postoperative radiotherapy 
(PORT), as definite treatment in unresectable TETs and 
in the neoadjuvant setting. Palliative radiotherapy for 
metastatic TETs is a feasible option either with typical 
conventional fractionation or stereotactic body radiation 
therapy (SBRT) (26). Thoracic RT for TETs is generally 
well tolerated.
Postoperative radiotherapy
Some retrospect ive  s tudies  reported that  PORT 
after incomplete resection could prevent or postpone 
postoperative recurrence, and improve the survival of 
patients in locally advanced stages (Masaoka-Koga I–III). 
Given the lack of prospective evidence, several investigators 
have utilised the SEER database and other national data 
sets to investigate the role of PORT for TETs (13,30,43-53). 
Basse et al. were the first to report on a large cohort of 
828 consecutive patients with resected TETs, for whom 
a guidelines-based decision for PORT was prospectively 
made at an expert MDT. Data of this study indicate that 
the ESMO guidelines algorithms for PORT are relevant in 
routine clinical practice (23) (Figure 2).
Resectable stage I-II thymoma
In stage I thymoma, excellent local control rates after 
surgery were achieved in several studies, and there is 
no indication for PORT in this setting (17,45,47). In a 
randomised trial investigating PORT in 26 patients with 
stage I TETs did not demonstrate a survival benefit (54). 
This finding is consistent with one of the largest database 
analysis with 1244 patients in, which no significant impact 
on survival was shown with the use of PORT (49). 
PORT is more controversial in stage II TETs. With 
R0 resection, many series report recurrence rates of <10% 
with or without PORT at 10 years. In a Japanese cohort 
of 257 stage II thymomas receiving PORT or surgery 
only, no difference was found with regards to recurrence 
rate (22). In contrast, PORT resulted in a trend towards 
Figure 2 Treatment algorithm for resectable TET (Masaoka-Koga stage I-III) adapted from on the ESMO and RHYTHMIC network 
guidelines (25). R0, microscopically margin-negative resection, R1, removal of all macroscopic disease, but microscopic margins are positive 
for tumor; I-III, Masaoka-Koga stage; A, AB, B1−3, WHO subtype; PORT, postoperative radiotherapy.
Upfront surgery Upfront surgery
Thymic carcinomaThymoma
A, AB, B1, B2
I, IIA−B IIA−B, III
Follow-up Follow-upPORT PORT PORT
A, AB, B1B3 B2, B3
R0 R0
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a survival benefit of 19 months (134 versus 115 months, 
P=0.09) in 1,334 stage IIB thymoma patients of a SEER 
database analysis. After excluding patients surviving less 
than 4 months in this stage (4-month mortality 11.6% for 
the surgery only group and 0.6% for the PORT group), the 
difference in survival was not significant (P=0.45) (47).
In a subset analysis of the study of Jackson et al., 
including 633 patients, the impact of PORT for stage 
IIA did not reach significance but indicated longer OS in 
association with PORT for patients with stage IIB thymoma 
(P=0.004) (49). These findings align well with a study of 
the ITMIG database, which might provide the strongest 
evidence for PORT to date, supporting the use of PORT 
in stage II thymoma, even when completely resected; the 
greatest benefit was observed for the histologic subtypes 
WHO B1−3 (52). In the only prospective study of Basse et al. 
PORT was most commonly offered in B3 subtype TETs (23). 
While the most recent ITMIG study suggests that WHO 
types B1−3 benefit most from PORT (52), interestingly 
two NCDB studies demonstrate a greater benefit for the 
less aggressive WHO type A and AB (49,55). However, the 
ESMO/RYTHMIC guidelines recommend PORT only for 
stage IIA and B3 or stage IIB and B2−3 (23,25).
A survey among centres of ESTS members showed that 
in stage II thymoma, 61% of ESTS members consider 
PORT, while 39% of the centres state that they do not use 
PORT. However, most of the centres that offer PORT state 
the indication on an individual basis, depending on worse 
histological subtypes, incomplete resection and subdivision 
of stage II according to the Masaoka-Koga staging system 
into stage IIA and IIB (24).
For incompletely resected stage I−II thymoma tumours 
it is widespread practice to offer adjuvant RT to prevent 
local recurrence and improve survival (49).
Resectable stage III-IV thymoma
PORT is recommended after complete resection of stage 
III/IVA thymoma in an effort to prolong recurrence-free 
survival and OS (25). In R0 stage III, the benefit of RT is 
established (49,52). The large population-based study by 
Weksler et al. with 476 patients demonstrated an improved 
disease-specific survival (P=0.049) without significant 
improvement of OS for resected stage III thymoma with the 
addition of PORT compared to surgical resection alone (56). 
In the ITMIG study, completely resected stage III thymoma 
investigating PORT lead to 10-year OS rates of 79% with 
PORT versus 64% without (P=0.0005) (52). In contrast to 
these results, a pooled analysis of 13 retrospective studies 
compared PORT to no adjuvant treatment in thymoma 
stage II−III patients, no significant difference was observed 
(P=0.63) (57). Importantly, a potential selection bias with 
poorer prognosis patients receiving PORT cannot be 
excluded in the analysis of Korst et al.
If tolerable, aggressive multimodality treatment including 
induction chemotherapy, surgery and adjuvant RT may be 
considered in patients with localised stage IVA thymoma 
to improve their survival, although the benefit seems to be 
less pronounced than in stage III. Univariate analysis of the 
study from Modh et al. showed that patients with stage IVA 
disease or a poorer performance status had worse freedom 
from recurrence (17,58).
In cases of incomplete resection, PORT is usually 
proposed to reduce the risk of mediastinal progression 
(34,59). Patients also might benefit from an OS advantage 
with PORT after R+ resection (49). 
Resectable thymic carcinoma/thymic neuroendocrine 
tumours
Whereas some studies suggest that adjuvant therapy may 
not be necessary for early-stage TCs (60), the ITMIG 
and ESTS database analysis shows an improved OS for 
patients receiving PORT compared with those who do 
not receive RT (4). An analysis of the Japanese Association 
for Research on the Thymus (JART) database that only 
included TC cases stage II and III, aimed to assess the 
impact of PORT. PORT only improved recurrence-free 
survival but not OS of stages II and III TC patients (50). 
For R+ resected TCs and TNETs PORT is recommended 
(4,16,29,43,50,61). 
For TNETs there are even less clinical trials and thus less 
evidence on treatment effectiveness. A complete resection 
should always be attempted. TCs and TNETs are tumours 
with a high risk of recurrence, with recurrence rates from 
20% to 30% in stage I and up to 80% in advanced disease. 
PORT is optional for R0 resected stage I tumours, should 
be considered for stage II tumours and is recommended for 
stage III/IVA tumours (4,16,25,50). 
Neoadjuvant and/or adjuvant treatment is performed as 
in TCs (62).
The ESMO guidelines recommend that PORT should 
be started within three months after the surgical procedure 
on the basis of expert consensus (25).
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Outlook
The magnitude of the effect from PORT in different stages 
of disease has yet to be quantified. As no randomised or 
even prospective study has been conducted to assess the 
effect of PORT on recurrence rates or survival for advanced 
stage TETs, available guidelines are based on low levels of 
evidence (25,63). Due to a lack of high evidence and the 
potential for a multidisciplinary approach, TETs should 
be discussed in a MDT and patient preferences should be 
incorporated in the decision-making. Phase III clinical trials 
assessing PORT for TET are currently being conducted 
in the People’s Republic of China and enrolling patients 
with stage II or III completely and incompletely resected 
thymomas and thymic cancers (Table 1). In the future, 
hopefully the results of these trials will provide good data 
on outcomes improving our clinical decision making. 
Definitive radiotherapy 
Definitive RT can be performed in unresectable TETs, or 
when surgery cannot be performed due to poor performance 
status or co-existing medical conditions. Definitive RT also 
refers to RT delivered when a macroscopically incomplete 
(R2) resection was previously performed (25) (Figure 3).
Despite the lack of high-level evidence, definitive RT 
or chemoradiation (CRT) is generally performed for 
unresectable TETs (64). Most studies are retrospective, 
except for two prospective phase II  studies.  The 
landmark prospective trial of Loehrer et al. enrolled 23 
patients who received induction chemotherapy with the 
cyclophosphamide, doxorubicin and cisplatin regimen and 
subsequent definitive RT to a total dose of 54 Gy. This 
strategy resulted in an overall response rate of 70% and a 
5-year survival of 53%, comparing favorably with the results 
of incomplete resection (65). The largest prospective phase 
II trial is from Fan et al. with 56 patients evaluating the 
use of CRT with etoposide/cisplatin (EP) as the first-line 
treatment for advanced TETs (85.7% stage IV). The study 
demonstrated that intensity modulated radiation therapy 
with 54 Gy and EP is safe and effective for unresectable 
TETs. The objective response rate was 85.7%. The 5-year 
PFS of 29.5% and OS rate of 56.2% were promising (66). 
The results from these studies and other reports (64,67-70) 
indicate that a multimodality approach such as definitive 
CRT is an effective strategy, also for selected patients with 
advanced stage IVB thymomas or thymic carcinomas, even 
if the recommended first-line treatment in case of Masaoka-
Koga stage IVB TETs is definitive chemotherapy followed 
by surgery or definitive RT depending on response and goal 
of palliation (25).
The single-institution analysis of Hao et al. demonstrates 
that patients treated with SBRT had an excellent local control 
with low rate of acute toxicities, which suggests that SBRT is 
feasible for the patients with TETs who are unable to undergo 
either surgery or conventionally fractionated radiation therapy 
or as a palliative therapy for metastases of TETs (71).
Treatment planning in TETs
Radiation oncologists should consult the surgeon to assess 
the operative findings to help determine the target volume 
at risk. The clinical target volume (CTV) for PORT should 
encompass the entire thymus (for partial resection cases), 
surgical clips, and any potential sites with residual disease. 
The CTV should be reviewed with the thoracic surgeon (26).
When the tumour has been completely resected, 
minimum fields for PORT should encompass the pre-
operative extent of disease, as indicated by pre-operative 
imaging and regions of risk identified intra-operatively. The 
field may then encompass involved nodes and the site of a 
possible pleural implant.
Although TETs have been deemed radiosensitive for 
years, the benefit of dose escalation on local control has not 
been clearly been established. Arriagada et al. (72) reported 
similar local control rates with total doses inferior to 
48 Gy or superior to 60 Gy, while in more recent series, 
no improvement regarding local control was observed with 
doses of 50 or >60 Gy (73).
Radiation doses for the adjuvant setting are typically 
between 45 to 55 Gy in the adjuvant setting [45 to 50 Gy 
for clear or close margins (73-75), 54 Gy for microscopically 
positive (R1) resection margins (76-78) and 60-66 Gy in the 
definitive treatment setting or after incomplete (R2) resection 
(25,26,63,76,79,80)], using a standard fractionation of 1.8−2 Gy 
per day. For definitive concomitant CRT a radiation dose of 
54 Gy seems to be most commonly recommended (64). 
Novel techniques, such as IMRT or proton beam RT, 
may reduce long-term radiation toxicity and thereby 
favourably shift the risk-benefit ratio of RT. Because these 
patients are younger and often long-term survivors, the 
mean dose to the heart should be as low as reasonably 
achievable (26,81). The first prospective study has recently 
shown that proton beam therapy in thymoma and TC patients 
is safe and feasible (82). A retrospective single-institution study 
found that adjuvant IMRT might achieve better outcomes 
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Table 1 Brief overview of ongoing trials
Disease Intervention Comparator arm Overall statue Country
NCT02633553 Thymoma Masaoka-Koga II/III Adjuvant RT (50 Gy) No RT Recruiting China
NCT02014805 Thymoma Masaoka-Koga II−IIIB Adjuvant RT No RT Recruiting China
NCT02633514 Thymoma/TC R1/R2 Adjuvant CRT with cisplatin/
etoposide (60 Gy)
Adjuvant RT (60 Gy) Recruiting China



















than conventional RT as an adjuvant treatment of completely 
resected stage III thymoma patients (83). 
The impact of IMRT, proton beam therapy, optimal 
dosing and radiation field design have yet to be accounted 
for in future prospective studies.
Neoadjuvant treatment
Induction therapy followed by surgery may be useful for 
locally advanced thymic malignancies initially considered 
unresectable (26,35-41). Patients with advanced disease 
(Masaoka-Koga stage III/IVA) are candidates for induction 
chemotherapy with or without RT. Cisplatin-based 
combination regimens should be administered (84,85). 
Usually, two to four cycles are administered before 
reassessing resectability of the tumour. A cohort of 22 patients 
with locally advanced thymoma and TC (stage III/IV) 
has been analysed prospectively to assess the efficacy of 
neoadjuvant CRT. After neoadjuvant CRT, R0 resection 
could be achieved in a majority (77%) of patients. The OS 
benefit was higher for patients that could be downstaged. 
Induction CRT might therefore be a feasible option to 
achieve complete resection in patients with locally advanced 
and highly aggressive tumours and thereby potentially 
improve their survival (86). This treatment option is also 
mentioned in the ESMO/RYTHMIC guideline (Figure 2).
Systemic treatment 
Chemotherapy may be used in unresectable, advanced, 
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metastatic or recurrent tumours, either as induction 
chemotherapy before intended radical local treatment, in 
combination with radiotherapy as potentially curative radio-
chemotherapy, or as palliative systemic treatment.
Few studies have focused on the effectiveness of 
chemotherapy for thymoma. Postoperative chemotherapy 
is not recommended after R0–R1 resection of thymomas 
(25,29,33,63).
For patients with advanced TC stage II/III/IV, adjuvant 
chemotherapy is recommended, if not already administered 
in the neoadjuvant setting (33,63).
Chemotherapy only is  offered in patients with 
unresectable, metastatic tumours in palliative intent. 
Cisplatin-based multi-agent combinations are considered 
standard of care. The preferred regimen for thymoma is 
cisplatin/doxorubicin/cyclophosphamide (CAP) (87-90). 
For TC carboplatin/paclitaxel is the preferred regime for 
first-line therapy (91-100). 
Checkpoint inhibitors may be promising for refractory 
thymic neoplasms. Pembrolizumab has been studied in 
TC in a phase II trial and disease control was achieved in 
75% of patients with a median OS of 24.9 months (101). 
Grade 3 to 4 myocarditis has been reported in 5% to 9% 
of patients with TCs receiving pembrolizumab (101,102). 
Nivolumab is currently studied (NIVOTHYM trial) by 
the European Organization for Research and Treatment of 
Cancer (EORTC) in patients with TC or type B3 thymoma 
as a second-line treatment (ClinicalTrials.gov Identifier: 
NCT03134118). 
Recurrences
Recurrences of TETs occur frequently (~10–15% of all-
stage resected tumours) and should be treated similar to 
primary disease if possible. The question of complete 
resection of these lesions should be considered and if not 
deemed possible, re-administration of a previously effective 
treatment must be discussed especially (103). Previous 
irradiation to the same area may pose a significant limitation 
to radiotherapy.
Follow-up 
No prospective data are available to build recommendations 
on post-treatment oncological follow-up of patients. After 
primary treatment for resectable thymomas, NCCN 
guidelines recommend that surveillance for recurrence 
should include chest CT every 6 months for 2 years, then 
annually for 10 years for thymoma (104). MRI may be used 
for surveillance if patients cannot tolerate IV contrast and 
to decrease radiation if patients are young and are expected 
to be screened for many years. Given the risk of late 
recurrence for thymoma, surveillance should continue for at 
least 10 years. ESMO guidelines recommend for completely 
resected stage I/II thymomas CT scan every year for 
5 years, then every 2 years. For stage III/IV thymomas and 
TCs or after R1−2 resection CT scans every 6 months for 
2 years, and thereafter annually should be performed (26).
Patients with thymoma also have an increased risk for 
secondary malignancies, although no particular screening is 
recommended to detect these (3,105,106).
Conclusion
Radiotherapy plays an important role in the management of 
unresectable locally advanced thymic epithelial tumours. In the 
adjuvant setting RT remains debated, especially in completely 
resected stage II tumours, for which PORT may be more 
likely to benefit in the presence of aggressive histology (WHO 
subtype B2, B3) or extensive transcapsular invasion (Masaoka-
Koga stage IIB). For stage III thymoma, evidence suggests 
an OS benefit for PORT after complete resection. For 
incompletely resected thymomas stage II or higher PORT is 
recommended. Thymic carcinomas at any stage with positive 
resection margins should be offered PORT.  
Pragmatism and patient involvement are the key in this 
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